Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Parenteral nutrition for patients requiring caloric and amino acid intake when oral or enteral nutrition is not possible, insufficient, or contraindicated,Off-label: May be used in specific metabolic disorders requiring controlled amino acid and dextrose delivery
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Not applicable as a single drug. The components have varied half-lives: amino acids have a plasma half-life of minutes to hours (e.g., alanine ~15 min); dextrose has a half-life of 1.5-2 hours under normal conditions, prolonged in renal impairment or hyperglycemia. Clinical context: in total parenteral nutrition, continuous infusion maintains steady state. No terminal half-life for the mixture.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Dextrose undergoes glycolysis and oxidation via the citric acid cycle. Amino acids are deaminated and metabolized via ureagenesis and gluconeogenesis.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
The components of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER are nutrients and electrolytes that are metabolized or excreted via normal physiological pathways. Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (about 90%) and a small amount in feces. Dextrose is metabolized to carbon dioxide and water, with excess exhaled as CO2 (approximately 50-70% of glucose carbon) or excreted in urine if renal threshold exceeded. Electrolytes are excreted renally in proportion to intake and homeostasis. No single excretion route percentage applies to the mixture; for amino acids, renal excretion of metabolites (urea) accounts for >90% of nitrogen elimination.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids: variable, generally low (0-30%) bound to albumin and other plasma proteins. Dextrose: negligible protein binding. Electrolytes: calcium is ~40-50% bound to albumin and other proteins; magnesium ~30%; phosphate ~10-20%; others minimal. Overall, component-specific.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Not applicable as a single entity. Amino acids distribute into total body water (~0.5-0.6 L/kg). Dextrose distributes into extracellular fluid (~0.2 L/kg) initially, then intracellularly. Electrolytes distribute according to their physiological compartments. No meaningful Vd for the mixture.
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intravenous: 100% bioavailability as it is administered directly into the bloodstream. Not applicable to oral or other routes.
Intravenous: 100%.
For GFR 30-59 m L/min: reduce volume by 25-50%; monitor electrolytes. For GFR 15-29 m L/min: reduce volume by 50-75%; avoid if severe renal impairment. For GFR <15 m L/min: contraindicated unless on renal replacement therapy; use with caution and adjust electrolytes.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce amino acid dose by 50%; monitor ammonia. Child-Pugh Class C: avoid due to risk of hepatic encephalopathy; alternative nutrition may be needed.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Dose based on weight (kg) and caloric needs. Typical: 10-15 m L/kg/day initially, titrate to 20-30 m L/kg/day. Maximum dextrose infusion rate: 0.5 g/kg/hr for neonates, 1 g/kg/hr for older children. Use with caution in low birth weight infants.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Elderly patients often require lower doses due to decreased renal function; start at lower infusion rates (e.g., 1-2 m L/kg/hr). Monitor fluid balance, electrolytes, and renal function closely. Dose adjustment based on GFR is recommended.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
Not for intravenous infusion unless admixed with appropriate electrolytes and vitamins. Do not administer simultaneously with blood through the same infusion site because of risk of pseudoagglutination. Use with caution in patients with severe hepatic or renal disease.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Monitor fluid balance, electrolyte concentrations, and acid-base status,Risk of hyperglycemia, hyperosmolarity, and metabolic acidosis,Hepatic and renal impairment require dose adjustment,Contains aluminum which may be toxic with prolonged use,Use with caution in patients with heart failure or pulmonary edema
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component,Severe hyperglycemia or diabetes mellitus with ketoacidosis,Severe hepatic or renal failure (unless adjusted),Intracranial or intraspinal hemorrhage,Anuria (for electrolyte-containing formulations)
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
Do not administer with any oral food or enteral nutrition unless specifically ordered; interactions depend on individual patient condition. Concomitant use of oral hypoglycemic agents may require dose adjustment due to dextrose content.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, but no evidence of malformations. Second and third trimesters: no known fetal risks. However, hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia if maternal glucose control is poor.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Components are endogenous substances normally found in breast milk. Dextrose and amino acids are present in milk; no adverse effects expected. M/P ratio not established. Safe to use during breastfeeding when clinically indicated.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Pregnancy increases plasma volume and renal clearance, but dosing adjustments are not typically required. Monitor glucose and electrolyte levels to avoid hyperglycemia or electrolyte imbalances. Use standard parenteral nutrition guidelines with close monitoring.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
This formulation provides 4.25% amino acids and 25% dextrose with electrolytes and calcium for total parenteral nutrition. Contains sulfite-free preparation; confirm patient's sulfite allergy status. Monitor serum electrolytes, blood glucose, and liver function tests; adjust infusion rate to avoid refeeding syndrome in malnourished patients.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This medication is given intravenously to provide nutrition when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or fever.,You may need regular blood tests to monitor your blood sugar, electrolyte levels, and liver function.,Do not suddenly stop the infusion without consulting your healthcare provider.,Inform your healthcare provider if you have diabetes, as this solution contains dextrose (sugar).
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, b. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.